Early Prostate Cancer Antigen-2: a Novel Serum Specific Marker for Prostate Cancer Detection
Early Prostate Cancer Antigen-2 (EPCA-2) is a prostate cancer biomarker, newly identified via proteomics-based examination of alterations in nuclear structure. EPCA-2 shows a higher overall specificity than PSA. Thus, an immunoassay based on antibodies against an epitope of EPCA-2 more accurately differentiates between confined and non-confined disease than PSA or Gleason score.
GETZENBERG ROBERT H [US]
Type of Offer:
« More Biotech Patents